2025年欧洲科研衍生企业报告

EuropeanSpinoutsReport

2025AcademicspinoutsfromEuropeaninstituteshavecreated

massive

valueandaremakingup

anincreasinglylargershareofnewstartupgenerationDeep

tech

andLife

Sciences

spinouts

fromEuropeanuniversitiesarenow

worthnearly

$400B,

and

created

over

160kjobsacross

7.3k+

startups.Most

of

the

value,

39%,has

alreadybeen

createdby

spinoutslaunched

since

2015showing

an

accelerationin

the

value

creation.Spinoutsarealsobecoming

a

larger

part

of

the

ecosystem,

accounting

for

40%

ofDeep

TechandLife

Sciencesnewstartups

since

2019,

80%more

thanin

2010-2018,and

anevenlarger

share

of

scaleup

companies

and

enterprise

value

created.TopsegmentsforEuropean

universityspinoutsDeep

TechandLife

Sciencesare

about

on

par

for

spinout

value

created,

fundingraisedandunicorns.Deep

Tech

is

showing

a

wider

early-stage

andrecentpipeline

for

future

value

creation.BeyondBiotech

andPharma,

a

strong

spinout

startup

scene

ispresentin

AI

xDeep

Tech,MedicalDevices,Climate

Tech

&

Energy,and

Semiconductors.

Quantumhasnotably

created

strong

value

even

with

a

smaller

startup

scene.Mostof

Quantum

andPhotonics

startups

areresearchspinouts.Energy

&Climate

Tech,

especiallyNuclear,andSemiconductorsarealso

above

theDeep

Tech

average,

while

Defence,

SpaceandRoboticsareless

driven

by

academicspinouts.Topuniversitiesandcountriesby

spinout

valuecreatedUKuniversities

claim

the

two

top

spots

with

Oxford

and

Cambridge,

and

other

threein

the

top

ten.Switzerlandpunches

aboveits

weight

withEPFL

andETH

Zurich

coming

third

and

fourth,

andUniversity

of

Zurichin

thetop

ten.TUMunich

closes

the

top

five.TheUKleads

for

spinout

value

creation,

followedby

Germany,France,and

Switzerland.Whenlooking

at

the

value

createdper

capita,

Switzerland

stronglyleads,

followedbyDenmark,

Sweden,UK,Finland,

andBelgium.TopuniversitiesinEuropebyDeepTechandLifeSciencesspinoutSpinoutsas%of

VC-backedDeepTechandLifeSciencesstartupsbyvalue

createdsegment

in

EuropeKeyTakeaways(1/2) ETHZurich EPFLLausanneCombinedEnterprise

Valueof

spinoutsfromEuropeanuniversitiesand

research

centers

by

launch

yearSource:

Dealroom.co; University

of

BristolImperialCollege

London University

of

Zürich University

of

OxfordUniversityofCambridgedealroom.

co

TUMunichPage

/

2RANK

UNIVERSITY DTU#1#5#2#4#3#6#10#9#8#7

UCLRobustfundingenvironmentfor

EuropeanSpinoutsEuropeanuniversity

spinoutsinDeep

techandLife

Sciences

haveraised$7.9Bin

VC

fundingin

2025

so

far,

on

track

toreach$9.1Bby

the

end

of

the

yearand

surpasslast

yearʼs

total.Lookingbackatpre-pandemiclevels

in

2019,

funding

doubledup

in

amount.Thelargest

VCroundsinDeep

Tech

andLife

Sciencesspinoutsin

2025

showa

strong

focus

on

AI

&

Autonomy,

Quantum,

Space,MedicalDevicesandLife

Sciences,

and

Nuclear

energy.Venture

Capital

investment

in

European

DT

and

LS

research

spinoutsbystage▊$0–1m(pre-seed)

▊$1–4m(seed)

▊$4–15m(series

A)

▊$15–40m(seriesB)

▊

$40–100m(series

C)▊$100–250m(mega

rounds)

▊$250m+(mega+)Thereʼsstillanotablelackoflate

stagefundingNearly

50%

oflate

stage

funding

forEuropeanDeep

techand

Life

Sciences

spinouts

comes

from

outsideEurope,mainly

from

theUS.Thisdependencyhas

abit

easenedup

though,

the

domestic

shareatlate

stagehasbeen

53%in

2023-2025,

considerably

higher

thanlowerat

41%in

2018-2020,

and

especiallycompared

to

the

34%

of

2021-2022.At

early-stageinstead,

86%

of

the

capitalis

fromEuropeand

Europe

shows

a

strong

support

scene

with

alargenumber

of

university

ventures

funds,independent

spinout

specialists,

and

otherDeep

techandLife

Sciencesinvestors.VCfundinginEuropeanDeepTechandLifeSciencesspinoutsbysourceof

funds(2023-2025)▊Domestic

▊Rest

ofEurope

▊US

▊Asia

▊Rest

of

WorldAstrongexit

environment

for

EuropeanspinoutsM&Aactivity

forDeep

TechandLife

Sciences

spinoutshas

beenatitshighest

in

2024-2025,

whileIPOs

disappeared

after

2021.Overall,

2025isprojected

to

be

thesecond-strongest

year

for

exit

valueledby

six$1B+

exits.Switzerland,UK

and

Germanuniversitiesmadeup

all

six$1B+exitsin

2025

amongETH,

Oxford,EPFL,

andUniversity

of

Tübingen.US

corporates

and

funds

acquiredmost

of

the

spinoutsvalue,nearly$24B

since

2019.

Acquisitions

fromEuropean

playersmadeup

themajority

of

the

countand

around

⅓

of

the

total

value.

Asiaisalso

a

strong

exitroute,

especiallyJapan.Exitvalueandcountfor

VC-backedEuropeanDeepTechandLife

Sciencesspinouts▊M&A

▊IPO

&

SPACs▊ProjectedKeyTakeaways(2/2)dealroom.

coDealroom.co;Page

/

3Source:Recommendedspinout

terms●Spinout

terms

still

show

significant

variation

acrossuniversities,

countries,

andindividual

deals.

Guidelines

andprocesses

are

often

opaque

without

clearly

defined

criteria

that

can

streamline

the

spinoutprocess●Progresshas

surelyhappenedin

thelast

few

years,however,

with,

forinstance,meanuniversity

equity

stakes

decreasing

significantlyin

theUK

to

alignmore

withinternational

standards.However,national

guidelinesremain

optional,

aremissingin

some

countries,

and

focus

on

avoiding

the

worst

outcomesrather

than

achieving

themost

ambitious

ones.●Much

of

the

debatehas

focused

on

equity

stakes,but

other

deal

terms,

suchasroyalty

fees,

exit

fees,andboard

seats,are

alsopivotal.

The“time

to

spinout”is

also

a

critical

aspect

typicallynot

explicitly

setin

targets.

Academic

founders

shouldn't

spend

severalmonths

or

even

yearsinnegotiations.SuccessmetricsforTTOs,universities,and

governments●●Mostuniversity

spinoutreportinginEurope

at

thenational

anduniversitylevel

focuses

on

thenumber

of

spinoutsasa

unique

criterion,

a

far

from

comprehensive

view,

and

that

can

at

timesintroduce

wrongincentivesin

the

ecosystem.In

thisreport,

weproposea

set

ofparameters

thatbetterreflect

value

creation:

thenumber

of

spinouts

thatreach

success

milestones(VC-backed;$10M

funding;unicorns,$1B+exitsand

$100M+revenues),

combined

enterprise

value,

and

totalfundingraised.

Additionally,

jobs

created

andrevenue

generated

can

alsobeimportantparameters

which

we

touchupon

at

the

aggregatelevel.Keysupport

for

spinout

growth●●PoC

fundinghasbeenidentifiedaskey

to

overcoming

the

first“Valley

ofDeath”

for

spinouts,but

despite

someEU

and

nationalprograms,

funding

availability

foruniversitiesislimited.Increased

funding

foruniversities

torunPoC

couldhelp

significantlyboost

spinout

creationinEurope.Late-stage

fundingremainslimited

forEuropean

spinouts,

withalmosthalf

of

fundingat

the$100M+

stage

coming

from

outside

ofEurope.

SeveralnationalandEUinitiativesacrossEuropeare

trying

to

closepart

of

thelate-stage

funding

gap,

but

speed

andimplementation

detailsmatter

strongly.Cultural,mindsetchangeandincentivesPage/

4

Source:

Dealroom.co;●●Entrepreneurshipisincreasinglyrecognisedasa

thirdpillar

of

academia,alongside

teaching

andresearch.However,many

researchersinEurope

still

donot

consider

entrepreneurship

as

a

career

option,in

addition

to

apublication-focused

career.

Inmany

cases,

careerprogression

doesnotactively

select

for

an

entrepreneurialmindset,butuniversitieshavearange

of

financial

andnon-financialincentives

they

can

setup

to

change

thisdealroom.

coKeyrecommendationsDetailsin

slides

92-95EuropeanfirstroundinvestorinemergingtechnologiesAtlanticis

the

firstbelieverin

founders,

scienceandbold

ideas.Weleadpre-seedrounds

acrossEurope

withspeed

and

conviction,backing

ambitiousfounders

from

day

one

and

supporting

themhands-on,

especially

through

fundraising

andhiring.

Asa

thesis-driven

fund,

wehavebuiltdeep

expertisein

four

technologyareas:

AI

&Compute,Energy

&Climate,Industrial

&Robotics,and

Space

&

Security.Since

2016,

wehavepartnered

with

over150European

foundersin

their

earliest

days,including

thosebehind

category-definingcompanies

suchas

Choco,

GetYourGuide,Wandelbots,

Softr,Harmattan,

Again,

SynthflowandMirelo.Forus,

thereisno

'toobold'

or

'too

early'.

Justfounders

venturinginto

theunknown.Early-stageDeepTechandClimate

TechinvestorMITO

Technology

supports

the

growth

ofhigh-potentialideas

and

startups,providingfunding

forbothProof-of-Concept(PoC)projects

and

early-stage

startupsinEurope.Itsmissionis

tobridge

the

gapbetweenresearch

andmarket,helpingresearchers

andentrepreneurs

turn

theirideasinto

scalable

and

impactful

solution.In

2024,itintroducedits

second

fund,MITO

Tech

Ventures,

whichinvestsin

solutions

forindustrial

decarbonization,

with

the

goal

of

achievingNet

Zero.MITO

Technology

works

with

technology

transfer

officesin

topinstitutions

to

scout

deep

techopportunities

andintellectualpropertyleads

to

drive

growth

fromlab

tomarket

and

createimpact.Globalstartupand

venturecapitalintelligenceplatformDealroom.cois

a

globalintelligenceplatform

for

discovering

and

tracking

themostpromisingcompanies,

technologies

and

ecosystems.Clientsincludemany

of

the

worldʼs

foremostorganizations

suchas

Sequoia,

Accel,IndexVentures,McKinsey,BCG,Deloitte,Google,

AWS,

Microsoft,Stripe.Dealroompartners

closely

withlocal

techecosystem

development

agencies

and

enablers,

to

create

a

comprehensivemulti-dimensionalblueprint

of

the

tech

ecosystem,includingcapital,

talent,innovation,

entrepreneurship

and

overall

economic

dynamism.again

yi

mir

elo.

ai

P只IO只

spiN

N

cloud

wan

del

bots

ATUR

BEADS

⃞Tulu

m

Energy

deal

room.

codealroom.

co熹Page

/

5CambridgeinvestorinDeepTechandLifeScienceCambridgeInnovationCapital(CIC)

is

anestablished

VC

firmin

one

of

the

world’smostimpactful

science

and

technology

ecosystems,witha12-year

trackrecord

of

identifying,supporting

and

exiting

science-drivencompanies.EmbeddedintheUKinnovationecosystem

and

withprivileged

access

to

theUniversity

of

Cambridge,CIChasunparalleledaccess

to

exceptional

technical

founders.Working

closely

withitsinvestors,includingmajorpension

funds,

sovereign

wealth

fundsand

family

offices,CICprovides

access

tocarefully

constructedportfolios

groundedinscientificinnovation,long-term

value

creationandlastingpositiveimpact.

CICmanages

over£600million

of

capital

andinvests

across

deeptech

andlife

sciences,

from

cancer

therapies,genomic

diagnostics

and

surgicalrobotics,

to

AI,semiconductors

and

quantum

computing.Investorincompaniesbuildingon

OxfordscienceOxford

ScienceEnterprises(OSE)is

anindependent,billion-poundinvestment

company

that

finds,

funds

andbuildstransformational

science

and

technology

companies

emerging

from

Oxford’sworld-leadingresearch.Ourportfolio

of

companiesis

focused

acrossthreehigh-impact

sectors

-Deep

Tech,LifeSciences,

andHealthTech

-

with

the

ambition

of

tackling

some

of

the

world’s

greatest

challenges.

To

date,OSEhas

collaborated

with

over

300internationalinvestors,

collectivelyinvestingover

£3billioninmore

than100

groundbreaking

companies.CreatingambitiousscienceanddeeptechcompaniesintheNorthofEnglandVenture

capital

firmNorthern

Gritstoneis

seizing

theNorth

ofEngland'sinnovation

opportunity,

investingin

science

and

technology

startupssolving

globalproblems

with

thepotential

to

scale

worldwide.NorthernGritstone

was

foundedin

2021

inpartnership

with

theUniversities

ofLeeds,Manchester,

and

Sheffield,

withLiverpool

joining

thepartnershipin

2025.

These

four'NorthernArc'universities,

combinedhavemore

than16,000researchersgenerating

$1billion

(£750

million)inresearch

fundingannually,

92%

of

whichis

world-leading

orinternationallyexcellent.

TheNorthern

Arc

forms

a

crucialpart

of

theUK’s

tech

ecosystemin

an

economicregion

spanning

theNorth

West

ofEnglandand

connectinginto

West

and

South

Yorkshire冷cry

sg

ph

lux

pm

gma

icdealroom.

coPage

/6FoundersAllanBradley,T-Therapeutics,LexiconPharmaceuticals,Kymab,

andPetMedixDraganGrabulovski,

ArarisBiotechFrancescoSciortino,ProximaFusionJanGoetz,

IQMQuantum

ComputersLidiaPieri,SybillaBiotechStefanoBuono,

Advanced

Accelerator

Applications(AAA)

&

newcleoThéauPeronnin,

Alice

&BobTonyKouzarides,

Abcam,Chroma,and

Storm

Therapeutics

TorbjørnØlshøj

Jensen,

Again.biolnvestors,acceleratorsand

venturestudiosAndrew

Williamson,CambridgeInnovationCapitalChristopheMaire,

AtlanticDevikaThapar,

WilbeDuncan

Johnson,NorthernGritstoneEdBussey,OxfordScienceEnterprisesHermannHauser,

AmadeusCapitalPartnersLisaEricsson,KTHInnovation

&KTH

VenturesMassimilianoGranieri,MITO

TechnologyMilesKirby,DeeptechLabsStéphaniePut,QubicUniversitiesandTTOsAndreaCrottini,EPFLDuncanlvison,TheUniversityof

ManchesterFlorianKirschenhofer,MaxPlanckInnovationFrankFloessel,

ETHZurichGiuseppeConti,NetvalLies

Vanneste,

VIBMikkelSørensen,DTUSkylabRolandSiegwart,ETHZurichThomasRibeiro,CNRSInnovationTobiasRuzok,TUM

VentureLabsPublicentitiesandothersupportAlbertMascarell,MWCapitalBarcelonaAna

Avaliani,Royal

AcademyofEngineeringAndy

Williams,Oxford-Cambridge

SuperclusterBoard

ChristineHockley,BritishBusinessBankEstelleDhont-Peltrault,FrenchMinistryofHigherEducation

Researchand

SpaceFabianMehring,Bavaria'sStateMinister

forDigital

AffairsJamesGavigan,EuropeanCommission

–

JointResearchCentre

Michiel

Scheffer,EICPeterMaarten

Westerhout,TechleapRafaelLagunadela

Vera,SPRINDSacha

Wunsch-Vincent,WIPOThank

youtoallcontributors

for

their

valuedinsightLorenzoChiavariniHeadof

Research

dealroom.

coMichelleLamprechtHead

of

Corporate

AffairsKateSpencerHead

of

CommunicationsLeonardoMassaInvestmentDirectorLisaBedwellHeadofMarketingQuentinCallejaPrincipalAuthorsdealroom.

coPage

/

7dealroom.

coSpinouts

fromEuropeanuniversitiesDeepTechSpinoutsbased

on

tangibleengineeringinnovation

orscientific

advances

and

discoveriesapplied

for

the

first

time

as

aLifeSciencesSpinouts

developingnewdrugs

andtherapiesbasedon

chemicalprocessesor

derived

fromlivingorganisms.Italsoincludes

specificsoftwareandhardware

forbiotechandpharmalikebioreactors,cellcultures

tech,or

AI-drug

discovery.In

thisreport,

spinoutsare

companies

thatoriginatefromresearch

carriedoutinauniversityorresearchcenter.Inmany

cases,

theuniversity/research

centermighthold

equityin

thecompany,but

thatisnotarequirement

tobe

considereda

spinout.Theuniversity/research

centermighthavenon-equityagreements(suchasroyalty-only)

or

theremightbeno

formalagreement,but

still

aclearandfoundationallink

to

theinstituteʼsresearch.We

still

consider

those

casesas

spinouts(Thisisalso

the

case

forcountries

withprofessorprivilege,

suchas

Sweden)This

definition

showcases

and

benchmarks

the(societal)

valuecreatedbyuniversitiesandresearch

centers,not

the

economicbenefit

accruing

directly

to

theseinstitutes

fromresearch

commercialisation.We

donotcountcompaniesas

spinoutsif

they

werenot

started

fromuniversityresearch,

evenif

theyhavebeen

supported,accelerated,

orlicensed

some

technology

whichisnot

their

core

startingIP.More

details

canbe

foundedin

themethodology

section,page

99In

thisreport,

weexploreinnovationsinDeep

Tech,

as

well

asin

theLifeSciencessector.product,

often

aiming

to

solvesocietyʼsbiggestissues(e.g.

space,

semiconductors,nuclear,

quantum

andphotonics,batteries,novel

AI,…)Scopeof

thereportSource:Dealroom.co;Page

/

8Deep

Techis

technology

thatisbasedon

tangible

engineeringinnovation

or

scientific

advances

and

discoveries

applied

for

the

first

time

as

aproduct,

oftenaiming

to

solve

societyʼsbiggestissues.Practically,acompany

is

consideredDeep

Techbased

onPrimarycriteriaTime

tomarket

/Complexity:

Thecompanyis

working

witha

technology

that

takes

a

long

time

to

reach

market-ready

maturity

due

to

thecomplexity

and

novelty

of

the

research

and

development

involved.Itthusemploysalotof

highly

educated

staff

early

on

andmay

create

novel

hardware

orintellectualproperties.Capitalrequirement:

Thecompanyʼs

technology

shouldrequiresubstantialinvestment

to

fund

theresearch,development,

testing,and

scalingof

theproduct

or

service.SecondarycriterialPand

spinouts:companiesholding

significantIPand

commercializing

researchinnovationsaremorelikely

tobeDeep

TechMarketriskIf

the

technology

solvesone

of

the

worldʼsbiggestproblems,

there

willbeample

demandDeep

TechRegularTechTeamriskAcademicand

scientificbackgroundsmayhaveless

commercialexperienceDevelopmenttimesLongerinitialdevelopmentphaseCapexintensityOftenheavyCapEx

ahead

of

revenues

andPMFCompetitionriskOften

the

strong

technologyedgepreventscompetitionTechnologyriskNew

technologies

donʼt

always

workas

expectedDeepTech

definedDifferencesinriskprofileDeep

Tech

vsRegular

Tech

startupsSource:

The

2025EuropeanDeep

TechReportbyDealroom,Lakestar,

WaldenCatalystandHello

Tomorrowdealroom.

coPage

/

9Lifesciences

definedStartupsin(Health)Life

Sciences,also

commonlyreferred

toasBiotech

and

Pharma,

focuson

developingnewdrugsand

therapiesbased

on

chemical

processesorderived

fromliving

organisms

toimprovehuman

health.This

alsoincludes

companies

whoseprimary

focusis

software

andhardwareproducts

for

theLife

Sciences

sector,

suchasbioreactors,

cell

culture

technology,

proteomicsand

sequencing,

or

AI

drug

discovery.

These

companies,

sometimes

referred

toas

TechBio,areoften

considered

tobe

both

Life

Sciences

and

DeepTech;in

thisreport,

theyareassigned

toLife

Sciences

to

avoid

overlaps.Life

SciencesdoesnotincludeHealth

sectors

suchasMedicalDevices(deviceintended

tobeused

formedicalpurposesand

subjected

toregulatory

approval)

andDigital

Therapeutics(evidence-based

therapeuticinterventions

drivenbysoftware

toprevent,manage,

or

treatamedical

disorder

or

disease),

whichare

insteadincludedinDeep

Techif

they

fit

the

criteria

of

time

tomarket,

complexity,

capitalrequirement

andresearch-intensiveness.Itdoesnotincludebiotechapplications

in

sectorsbeyondhealth,

such

asagritechand

foodtech(e.g.

crop

engineering,

cultivatedmeat,precisionfermentation),

chemicalsandmaterials(e.g.biomaterialsandbiomanufacturing),

among

others.

Thosebiotech

companiesareincludedinDeep

Techif

they

meet

the

criteria

of

time-to-market,

complexity,

capitalrequirements,

andresearchintensity.DrugdevelopmentDevelopingnewdrugs

and

therapiesbasedon

chemicalprocesses

orderived

fromlivingorganisms

toimprovehumanhealth.TechbioBiotechbeyondhealthAgritech

andfoodtech,

chemicalsandmaterials,andothers.DigitalhealthDigital

therapeuticsand

othernovelscience

applied

todigitalhealthMedical

devicesDevicesintended

tobeused

formedicalpurposesandsubjected

toregulatoryapprovalBioreactors,cell

culturetech,proteomicsandsequencing,

AI-drugdiscovery,…Source:Dealroom.co;dealroom.

coPage/102

The

Spinout

StartupLandscape3

Top

Spinout

founders4

SectorDeepDives5

CountryDeepDives6

Recommendationsand

outlook7

Methodology

&appendix1Europeʼs

AcademicStrength&lnnovationPotentialPage

/11“IthasbecomefashionabletoclaimthatEuropehaslostits

innovativetouchandwillnevercatchupagain.Whilemuch

workisstillneeded,thereishopeandevidencetothecontrary.Indeed,theWIPOGlobalInnovationIndex2025places11Europeaneconomiesintheglobaltop20,andthis

reportshowshowthisstrengthisincreasinglyturninginto

impactwithincreasedresearchcommercializationthrough

spinouts.Moreresearch-driven

startupsand

spinoutsareemerging

fromEuropeanuniversitiesandpubliclabs,

funding

for

deep

techisgrowing,and

thepaceofresearch

commercialisationis

accelerating.

Europe

faceschallenges,butits

sciencebase,

talent,clusters

andspinoutecosystemgiveit

every

chancenot

just

to

stay

in

therace

for

frontierinnovation,but

tohelpdefine

thenext

waveof

breakthrough

technologies.

Welook

forward

to

working

withDealroomona

global

startupandspin-offlistfortheGII2026reportonʻFrontierInnovationandResearch-IntensiveEntrepreneurshipʼ,

tobe

releasedin

September

2026."Europehasastrongtalentpoolof

STEMgraduatesandresearches,andclaims

ahigh

shareof

globalpublicationsandpatentsTheEUaccounts

for

~19.2%of

theworldʼstop-10%most-citedpapers,almostonparwith

theUS.Europegenerated

also

~21.8%ofinternationalpatentapplications,

secondonly

to

AsiA,and

theEPOhitarecord

199kapplicationsin

2023,underscoring

strongR&D

andmarketattractiveness.Europeproducesonemillion

and

ahalf

STEM

graduatesper

year,

widelymore

than

theUS,

withrising

STEMgraduationrates.Europeʼsalsoboastsahuge

apool

of

2.15M

researchers(FTE)and

~40%

ofEU

doctoral

studentsarein

science

&

tech

fields.European

cities

dominate

globalliveability

rankings,apotentialpull

for

foreign

talent.Europe

has

one

of

the

highest

R&D

spending

as%of

GDP,

withmany

countries

dedicatingreaching

2-3%

of

GDP.HorizonEuropeis

thelargestpublic

fundingprogram

forR&Din

the

world,

withabudget

of

€95.5billion(or

€93.5billionin

some

figures)

for

the

2021-2027period.Europehosts11economiesranked

among

the

global

top

20,including

sixin

the

top10in

the

GlobalInnovationIndex2025byWIPO,

which

looksat

Scienceand

innovation

investment,Technologyadoption,and

Socioeconomic

impact.SachaWunsch-VincentCo-EditorGlobalInnovationIndex

&Head,

Section,Economics

&Data

Analytics,WIPOLeadingpublication

andIPStronginnovation

economyStrong

talentpoolStrong

R&DSource:

WIPO,Eurostatdealroom.

coPage/12EngineeringEurope

hosts

3of

the

top10universities

globallyfor

Engineering,and

5of

the

top

20.工M

P

E

R

工A

LComputerSciencesEurope

hosts4of

the

top10universities

globallyfor

Computer

Sciences,and6

of

the

top

20.

ETHzii

rich

EPFLEuropehosts

30%

the

top

universities

acrossDeep

TechandLife

SciencesdomainsLifeScienceEurope

hosts

2of

the

top10universities

globallyforLifeSciences,and

6

of

the

t